Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,204 across all filing types
Latest filing 2019-03-20 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Updates
Regulatory Filings
2019-03-20 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice of an Extraordinary General Meeting (EGM) for Strides Pharma Science Limited, scheduled for March 27, 2019. It includes the agenda items, such as divestment of the Australian business and approval for transactions with a related party. The document contains the full text of the EGM notice, explanatory statements pursuant to Section 102 of the Companies Act, 2013, and procedural details about voting and proxies. There is no financial data or results reported, nor is it a transcript or presentation. It is not an announcement of voting results but the notice itself. Therefore, the document fits the category of a meeting notice for an Extraordinary General Meeting, which is best classified under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) if it were results, but since this is the notice and agenda for the meeting, it is more aligned with a Proxy Solicitation & Information Statement (PSI) or meeting notice. Given the options, the closest and most appropriate classification is PSI, as it includes materials sent to shareholders to provide information and request votes for meetings.
2019-03-05 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific pharmaceutical product, Ethosuximide Softgel Capsules. It is not a financial report, regulatory filing, or any form of shareholder meeting material. The content focuses on a product approval and commercial plans, typical of a Capital/Financing Update or corporate announcement related to business operations. Given the nature of the announcement about product approval and market launch, the most appropriate classification is Capital/Financing Update (CAP). The document length is short (4285 characters) and is clearly a press release, not a report or regulatory filing. Confidence is high due to clear content and context.
2019-02-20 English
Press Release
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Strides Pharma Science Limited has received USFDA approval for a specific pharmaceutical product. It is a short communication (3756 characters) focused on a regulatory approval event and product marketing plans. There is no financial data, no detailed report, no meeting materials, no voting results, no management discussion, or other regulatory filings. It is not an announcement of a report publication but a standalone press release about a product approval. This fits best under the category of Capital/Financing Update (CAP) as it relates to a significant business development impacting the company's product portfolio and market presence, which is typical for CAP filings. The confidence in this classification is high given the clear nature of the document as a press release about a regulatory approval and product launch.
2019-02-13 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a short announcement addressed to stock exchanges regarding the receipt of an Establishment Inspection Report (EIR) from the USFDA confirming the successful closure of inspections at the company's manufacturing facility. It does not contain financial data, detailed reports, or regulatory filings beyond this notification. The document is brief (1583 characters) and serves to inform the market about a regulatory inspection outcome rather than presenting a financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-02-06 English
ESOP/ESOS/ESPS
Capital/Financing Update Classification · 95% confidence The document is a formal letter addressed to stock exchanges regarding the grant of stock options under an ESOP scheme. It details the number of options granted, the exercise price, vesting period, and exercise window. There is no financial data, report, or presentation included. The content is an announcement of a capital-related event (grant of stock options) rather than a full report or regulatory filing. Given the nature of the announcement about stock options, it fits best under Capital/Financing Update (CAP). The document length is short and does not contain financial statements or detailed analysis, so it is not an Annual Report or Interim Report. It is not a Regulatory Filing (RNS) because it is a specific capital update. Therefore, the classification is CAP with high confidence.
2019-01-29 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.